ABVX:EPA
Abivax SA
€78.00
arrow_downward
-1.20%(-0.95) 1D
Oct 19, 4:36:57 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€79.00
High
€79.90
Low
€71.10
Mkt. cap
6.83B
Avg. vol.
121.63K
Volume
145.65K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€79.00
High
€79.90
Low
€71.10
Mkt. cap
6.83B
Avg. vol.
121.63K
Volume
145.65K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
finance.biggo.com
·
42 minutes ago
He makes 3 decisions a year (and beat the S&P 500 for 11 years)｜My First Million
TradingView
·
32 minutes ago
S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
RealMoney Pro
·
33 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
Insider Monkey
·
1 hour ago
Apple Has Outperformed the S&P 500, but is AAPL’s 35x Valuation Getting Ahead of its Growth?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com